Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
Disease expertise and patient data recognized by FDA and EMA as important sources of evidence to inform decision making.
Clinical registries offer unique data solutions, including rich clinical data, to provide differentiated insights to biopharma and biotech. Their contribution can span the product life cycle, from early clinical development to product launch, to post-authorization safety and effectiveness studies. Registry-based studies are growing specifically in rare diseases, and because traditional electronic medical record (EMR) databases do not capture the clinical and patient outcomes found in registries. Whether using one registry or several simultaneously to ensure sufficient data, registry groups are important partners in generating real-world evidence to advance treatments.
This webinar discusses how a strategic team with registry expertise can help a company:
- Evolve and grow the use of registries
- Identify the right study approach
- Understand the importance of successful partnerships
- Identify use cases of registry-based studies
- Integrate the use of data science in data curation and analysis
- Overcome challenges of coordinating multiple registries
